Ticker
ABBV

Price
171.14
Stock movement down
-4.13 (-2.36%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - General
Market cap
302.21B
Ent value
424.97B
Price/Sales
5.55
Price/Book
37.56
Div yield
3.62%
Div growth
10.52%
Growth years
9
FCF payout
48.65%
Trailing P/E
50.43
Forward P/E
14.19
PEG
6.10
EPS growth
-5.70%
1 year return
25.30%
3 year return
13.46%
5 year return
19.87%
10 year return
12.05%
Last updated: 2024-07-18

iO Charts is a Seeking Alpha partner

BUSINESS INSIGHT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

iO Charts is a Seeking Alpha partner

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share6.20
Dividend yield3.62%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.53%
Minimum yield3.22%
Discount to avg yield-25.13%
Upside potential-20.08%
Yield as % of max yield49.51%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.62%
Current yield distribution92.70%
Yield at 100% (Min)3.22%
Yield at 90%3.66%
Yield at 80%3.81%
Yield at 50% (Median)4.38%
Yield at 20%5.21%
Yield at 10%5.70%
Yield at 0% (Max)7.32%

Dividend per share

Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share6.20
Payout frequencyQuarterly
Ex-div date15 Jul 2024
EPS (TTM)3.38
EPS (1y forward)12.06
EPS growth (5y)-5.70%
EPS growth (5y forward)8.27%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
ABBVS&P500
DGR MR4.73%10.29%
DGR TTM4.79%4.92%
DGR 3 years7.84%5.24%
DGR 5 years10.52%5.40%
DGR 10 years-7.07%
DGR 15 years-6.12%
Time since last change announced267 days
EPS growth (5y)-5.70%
EPS growth (5y forward)8.27%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM177.71%48.65%
Average--
Forward51.41%-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E50.43
Price to OCF13.32
Price to FCF13.81
Price to EBITDA14.72
EV to EBITDA20.70

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales5.55
Price to Book37.56
EV to Sales7.81

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count1.77B
EPS (TTM)3.38
FCF per share (TTM)12.35

Income statement

Loading...
Income statement data
Revenue (TTM)54.40B
Gross profit (TTM)37.21B
Operating income (TTM)14.28B
Net income (TTM)5.99B
EPS (TTM)3.38
EPS (1y forward)12.06

Margins

Loading...
Margins data
Gross margin (TTM)68.40%
Operating margin (TTM)26.25%
Profit margin (TTM)11.02%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash18.07B
Net receivables11.95B
Total current assets38.87B
Goodwill33.43B
Intangible assets62.23B
Property, plant and equipment11.72B
Total assets148.87B
Accounts payable31.26B
Short/Current long term debt74.00B
Total current liabilities41.52B
Total liabilities140.83B
Shareholder's equity8.05B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)22.69B
Capital expenditures (TTM)795.00M
Free cash flow (TTM)21.89B
Dividends paid (TTM)10.65B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity74.47%
Return on Assets4.03%
Return on Invested Capital7.30%
Cash Return on Invested Capital26.68%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open174.44
Daily high176.68
Daily low170.72
Daily Volume5.94M
All-time high182.10
1y analyst estimate184.08
Beta0.58
EPS (TTM)3.38
Dividend per share6.20
Ex-div date15 Jul 2024
Next earnings date25 Jul 2024

Downside potential

Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-6.02%-2.16%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-13.95%-11.26%
Avg time to new high18 days12 days
Max time to new high975 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
302.21B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Employees
50000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...